Literature DB >> 23369881

An HPLC-MS/MS method for simultaneous determination of decitabine and its valyl prodrug valdecitabine in rat plasma.

Youxi Zhang1, Jin Sun, Yikun Gao, Ying Kong, Youjun Xu, Weiru Jia, Chuanrong Liao, Peng Zhang, He Lian, Xiaopeng Han, Dongpo Li, Yajie Geng, Zhonggui He.   

Abstract

A simple and sensitive HPLC-MS/MS method was developed and validated for the simultaneous determination of decitabine and valdecitabine in rat plasma. The analytes were separated on a C(18) column (150mm×4.6mm, 3.5μm) and a triple-quadrupole mass spectrometer equipped with an electrospray ionization (ESI) source was applied for detection. A clean solid-phase extraction procedure with cation exchange cartridge was employed to extract the analytes from rat plasma with high recovery of decitabine (>82%). The calibration curves were linear over a concentration range of 10-10,000ng/mL for decitabine and 5-500ng/mL for valdecitabine. The lower limit of quantitation (LLOQ) of decitabine and valdecitabine was 10 and 5ng/mL, respectively. The intra-day and inter-day precisions were less than 15% and the relative error (RE) was all within ±15%. The validated method was successfully applied to a pharmacokinetics study in rats after either decitabine or valdecitabine orally administrated to the Sprague-Dawley rats.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23369881     DOI: 10.1016/j.jchromb.2012.12.040

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  3 in total

1.  Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity.

Authors:  Xiaoyan Wu; Zhenhua Hu; Sara Nizzero; Guodong Zhang; Maricela R Ramirez; Ce Shi; Jin Zhou; Mauro Ferrari; Haifa Shen
Journal:  J Control Release       Date:  2017-10-16       Impact factor: 9.776

2.  Tracking Decitabine Incorporation into Malignant Myeloid Cell DNA in vitro and in vivo by LC-MS/MS with Enzymatic Digestion.

Authors:  Sujatha Chilakala; Ye Feng; Lan Li; Reda Mahfouz; Ebrahem Quteba; Yogen Saunthararajah; Yan Xu
Journal:  Sci Rep       Date:  2019-03-14       Impact factor: 4.379

3.  Development and validation of a UPLC-MS/MS assay for the determination of gemcitabine and its L-carnitine ester derivative in rat plasma and its application in oral pharmacokinetics.

Authors:  Gang Wang; Dongyang Zhao; Hongxiang Chen; Dawei Ding; Longfa Kou; Lifang Sun; Chenxia Hao; Xincong Li; Kai Jia; Qiming Kan; Xiaohong Liu; Zhonggui He; Jin Sun
Journal:  Asian J Pharm Sci       Date:  2017-01-09       Impact factor: 6.598

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.